ARIBIO-CO-LTD
AriBio, a clinical-stage biopharmaceutical company based in South Korea, announced today, June 17th 2020, the completion of enrollment in a Phase 2 study of AR1001, a first in class, orally dosed investigational drug for mild to moderate Alzheimer’s disease. A total of 210 patients are enrolled in the study, and the company is expecting to announce the topline results by early 2021.
“The completion of enrollment is a significant milestone for AriBio, and the company is extremely thankful for the combined efforts of our researchers, partners and the patient community. Advancing safe, effective and meaningful therapies for this devastating disease is our top priority at AriBio, and we look forward to presenting this data in the future,” said James Rock, Senior Vice President of Clinical Operations.
“Patients participating in the study are showing extremely low drop-out rates despite the COVID-19 pandemic and the safety profile of the drug has been encouraging,” said Matthew Choung, Chairman and CEO.
AriBio is the first company from South Korea to fully enroll a Phase 2 study for Alzheimer’s disease in the United States. The company aims to initiate another Phase 2 study for Mixed Dementia in 2021.
About AR1001
AR1001 is a first in class oral therapy with novel polypharmacological mechanisms for the treatment of Alzheimer’s disease. Pre-clinical studies have confirmed neuroprotective effects of AR1001 via inhibiting neuron apoptosis and restoring synaptic plasticity. AR1001 also has demonstrated positive effects against amyloid plaques and tau proteins.
About AR1001-ADP2-US01
AR1001-ADP2-US01 (NCT03625622) is A Double-Blind, Randomized and Placebo-Controlled Study to Evaluate Efficacy and Safety of 26-Week Treatment of AR1001 in Patients with Mild to Moderate Alzheimer's disease. The study aims to assess the safety and efficacy of AR1001 in slowing the progression of Alzheimer's disease through various cognitive and functional assessments. Last patient visit is expected to occur by the end of 2020. The details of the clinical trial are available at ClinicalTrials.gov.
About AriBio Co., Ltd.
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with a focus on neurodegenerative and infectious diseases. AR1003 is the lead candidate for sepsis and COVID-19, which is preparing to enter a Phase 1 study in the United States by early 2021.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200617005630/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Guidewire Signs Definitive Agreement to Acquire ProNavigator28.10.2025 14:00:00 CET | Press release
AI-powered knowledge management platform puts expertise at the fingertips of every insurance professional CONNECTIONS CONFERENCE--Guidewire (NYSE: GWRE) today announced that it has entered into a definitive agreement to acquire ProNav Technologies Ltd. (d/b/a ProNavigator), a knowledge management platform purpose-built for the P&C insurance industry. ProNavigator delivers precise, context-aware best practice information directly within insurance workflows, helping professionals work faster and more effectively. Its platform captures, connects, and surfaces institutional knowledge across claims, underwriting, and distribution. Used by 34 insurance organizations, including 12 shared customers with Guidewire, ProNavigator helps increase productivity, reduce claim cycle times, personalize customer service, and accelerate employee onboarding. Once the acquisition is complete, Guidewire will integrate ProNavigator’s insurance-trained intelligence across its platform, delivering advanced sear
Rimini Street Introduces Agentic AI ERP in Groundbreaking White Paper28.10.2025 14:00:00 CET | Press release
Rimini Street declares ERP Software dead and unveils Agentic AI ERP, a next generation, transformative ERP technology that delivers innovation faster, better and cheaper with more agility, deployed over existing ERP Software with no required, costly ERP upgrades Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced the publication of its latest thought leadership white paper, The Rise of Agentic AI ERP. This landmark document presents a vision and roadmap for the next-generation technology and tools that will eventually replace today’s ERP Software which has become too big, complex, inflexible and expensive to meet the needs of a fast-changing world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251028696910/en/ Rimini Street In
Gurobi Appoints Dr. Oliver Bastert as Chief Technology Officer28.10.2025 14:00:00 CET | Press release
Dr. Bastert leads Gurobi’s R&D team, advancing innovation in the company’s optimization technology. Gurobi Optimization, LLC, the leader in decision intelligence technology, is pleased to announce the appointment of Dr. Oliver Bastert to the role of Chief Technology Officer, leading the company’s Research and Development team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251028639754/en/ Dr. Oliver Bastert, CTO, Gurobi Optimization "We are thrilled to have Dr. Bastert onboard as our Chief Technology Officer,” said Duke Perrucci, CEO of Gurobi Optimization. “Oliver plays a pivotal role in advancing our solver and driving innovation. As we continue our mission to bring optimization everywhere, his leadership will be instrumental." Dr. Bastert joined the Gurobi team in February and brings over 20 years of experience in B2B software, SaaS, and AI technologies. Prior to joining Gurobi, he served as Vice President of Product Man
Fortegra Insurance UK Limited Achieves NAIC Alien Insurer Registration28.10.2025 14:00:00 CET | Press release
Fortegra Insurance UK Limited, part of the Fortegra Group — a global specialty insurer — has been officially admitted to the National Association of Insurance Commissioners (NAIC) Quarterly Listing of Alien Insurers, formalized in the NAIC’s October Edition 249. The registration creates a differentiated platform that enables Fortegra’s agents and brokers in the United Kingdom to serve their customers who need specialized U.K.-domiciled capacity to address risks that require a U.S. surplus lines solution. “Our alien insurer listing offers UK Managing General Agents (MGAs) a straightforward way to access U.S. surplus lines business. Additionally, our strong presence in the London market fosters natural connections among brokers and agents, as well as the capacity to address complex risks. This combination of strengths sets us apart in the marketplace and allows us to uphold our rigorous underwriting standards while pursuing selective growth with high-quality program partners,” said Richa
Nine-in-10 Legal Leaders Brace for Sharp Rise in Online IP Infringement as AI Accelerates Attacks28.10.2025 14:00:00 CET | Press release
85% report an increase in IP infringements over the past 12 months, 90% are expecting more in the year ahead 88% say AI-enabled systems are driving an increase in infringement activity More than half (56%) already outsource some activity—a trend expected to rise Nine-in-10 (91%) senior legal professionals are concerned about the threat of online intellectual property (IP) infringement, according to new research commissioned by CSC, the leading provider of global business administration and compliance solutions.While 85% report an increase in IP infringements at their firms over the past 12 months, 90% are expecting more in the year ahead with 89% predicting continued escalation over the next three years. While the most common forms of IP infringement are rated as counterfeiting, trademark abuse, and brand impersonation, all of which can erode consumer trust and inflict long-term financial and reputation damage, the threat of artificial intelligence (AI) looms large—88% say AI-enabled s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom